Biomarker for ovarian cancer ctap3-related proteins
AssigneesVermillion, Inc., The Johns Hopkins University
InventorsZHEN ZHANG, DANIEL W. CHAN, ERIC T. FUNG, ZHENG WANG, FUJUN ZHANG
Life of this patent
Estimating the term…
Abstract
The present invention provides a protein-based biomarker that is useful in qualifying ovarian cancer status in a patient. In particular, the biomarker of this invention is useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarker can be detected by SELDI mass spectrometry.
Claims8
1-35. (canceled)
A panel of biomarkers for the diagnosis of ovarian cancer comprising ApoA1, Beta-2 microglobulin, and CA125.
A panel of biomarkers consisting of ApoA1, Beta-2 microglobulin, CA125, transthyretin, and transferrin.
A method for diagnosing ovarian cancer, the method comprising measuring the level of the panel of biomarkers of claim 1 using an immunoassay or mass spectroscopy.
The method of claim 1, wherein the panel comprises ApoA1, Beta-2 microglobulin, CA125 and transthyretin or transferrin.
The method of claim 1, wherein the panel consists of ApoA1, Beta-2 microglobulin, CA125, transthyretin, and transferrin.
Dependencies are inferred from the claim text.